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SHORT ABSTRACT:34
A reference measurement procedure for absolute quantification of Aβ1-42 in human CSF35
based on solid-phase extraction and liquid chromatography tandem mass spectrometry36
is described.37
38
LONG ABSTRACT:39
Alzheimer’s disease (AD) is the most common neurodegenerative disease among the40
elderly and accounts for 60-80% of all cases of dementia. Currently, the diagnosis of AD41
is based on cognitive tests and mental state exams, but the peptide amyloid-beta (Aβ) in 42
cerebrospinal fluid (CSF) is increasingly used in clinical trials and settings. As for most43
protein and peptide biomarkers, quantification is performed using antibody-based44
techniques such as enzyme-linked immunosorbent assay (ELISA). However, intra- and45
inter-laboratory variability of these assays hamper its use as a diagnostic marker in46
clinical routine.47
48
An antibody independent Reference Measurement Procedure (RMP) was developed49
based on solid-phase extraction (SPE) and liquid chromatography (LC)-tandem mass50
spectrometry (MS/MS), where stable isotope labeled Aβ peptides were used as internal 51
standards, enabling absolute quantification. A high-resolution quadrupole-orbitrap hybrid52
instrument was used for measurements. The method allows quantification of CSF Aβ1-4253
between 150-4000 pg/mL.54
55
INTRODUCTION:56
Alzheimer’s disease (AD) is the most common form of dementia and affects about 3557
million people worldwide1. Neuropathological hallmarks of the disease widely believed to58
lie at the core of AD pathogenesis are intracellular neurofibrillary tangles of59
hyperphosphorylated tau protein2, and extracellular plaques consisting of aggregated60
amyloid-beta (Aβ) peptides3. In line with this, assessment of plaque pathology in vivo by61
biomarkers has recently been included in the research diagnostic criteria for AD4. For62
CSF measurements of Aβ1-42, several immunoassays are available and used in many63
clinical laboratories5. The concentration of Aβ1-42 in CSF is approximately 50% lower in64
AD patients than in cognitively normal elderly, reflecting the deposition of the peptide in65
plaques in the brain6,7.66
67
These biomarkers are mainly analyzed using immunoassays, i.e., antibody based68
techniques, but these assays may be influenced by matrix effects8. The use of69
immunoassays on different technology platforms and lack of assay standardization9,1070
makes the introduction of global cut-off concentrations difficult11,12. An analytically71
validated RMP would permit uniform calibration of different assay platforms, ideally72
resulting in better comparability across analytical platforms, and better control of factors73
contributing to the overall measurement variability.74
75
Absolute quantification of Aβ1-42 using the developed LC-MS/MS method overcomes76
many of the issues associated with antibody-based methods. The method, listed as an77
RMP by the Joint Committee for Traceability in Laboratory medicine (JCTLM database78
identification number C11RMP9), will be used determine the absolute concentration of79
Aβ1-42 in a Certified Reference Material (CRM) to harmonize CSF Aβ1-42 measurements80
across techniques and analytical platforms. The described workflow should be of81
relevance for the development of candidate reference methods for peptides and proteins82
within other areas of medicine.83
84
PROTOCOL:85
86
Note: This protocol requires aliquots of at least 50 µL with a concentration of 50 µg/mL87
for each Aβ peptide as starting material. The Aβ peptides should be dissolved in 20% 88
acetonitrile (ACN) and 4% concentrated ammonia solution in deionized water (v/v) and89
stored at -80 °C.90
91
Caution: See Table 1 for safety information.92
93
1. Preparation of solutions94
1.1) Prepare 100 mL of 20% ACN and 4% concentrated ammonia solution in deionized95
water (v/v) by diluting 20 mL ACN and 4 mL concentrated ammonia (~25%) in deionized96
water. Adjust the final volume to 100 mL with deionized water. Make fresh daily.97
98
1.2) Prepare 50 mL of 5 M guanidine-hydrochloride by dissolving 26.08 g guanidine-99
hydrochloride in deionized water to a final volume of 50 mL. Store at 20 °C and make100
fresh monthly.101
102
1.3) Prepare 200 mL of 4% phosphoric acid in deionized water (v/v) by diluting 9.4 mL103
concentrated phosphoric acid (~85%) in deionized water. Adjust the final volume to 200104
mL with deionized water. Store in the refrigerator and make fresh weekly.105
106
1.4) Prepare 50 mL of 75% ACN and 10% concentrated ammonia solution (v/v) in107
deionized water by diluting 37.5 mL ACN and 5 mL concentrated ammonia (~25%) in108
deionized water. Adjust the final volume to 50 mL with deionized water. Make fresh109
daily.110
111
1.5) Thaw at least 2.5 mL human CSF for the calibrators,.obtained from de-identified112
leftover samples from clinical routine analysis.113
114
1.6) Prepare artificial CSF containing 150 mM Na, 3.0 mM K, 1.4 mM Ca, 0.8 mM Mg,115
1.0 mM P and 155 mM Cl in deionized water and add bovine serum albumin to a final116
concentration of 4 mg/mL. Only 1 mL is needed per analysis but prepare a large volume,117
aliquot and store for future use.118
119
2. Preparation of calibrators120
2.1) Prepare 0.5 mL 4 µg/mL 15N-Aβ1-42 peptide by adding 40 µL of 50 µg/mL 15N-Aβ1-42121
to 0.46 mL 20% ACN and 4% concentrated ammonia in a 0.5 mL microcentrifuge tube.122
Mix on vortex mixer for one minute.123
124
2.2) Prepare 2 mL 100 ng/mL 15N-Aβ1-42 peptide by adding 50 µL of the 4 µg/mL125
15N-Aβ1-42 to 1.95 mL 20% ACN and 4% concentrated ammonia in a 2 mL126
microcentrifuge tube. Mix on vortex mixer for one minute.127
128
2.3) Prepare six calibrator solutions (A-F) by mixing the volumes of each solution129
indicated in Table 2. Use 0.5, 1.5 and 2 mL microcentrifuge tubes. Mix on vortex mixer130
for one minute.131
132
2.4) Prepare the final calibrators (in duplicate) in 0.5 mL microcentrifuge tubes by adding133
corresponding calibration solutions and human CSF according to Table 3. Mix on vortex134
mixer for one minute.135
136
3. Preparation of internal standard137
3.1) Prepare 2 mL 0.8 µg/mL 13C-Aβ1-42 peptide by adding 32 µL of 50 µg/mL 13C-Aβ1-42138
to 1.968 mL 20% ACN and 4% concentrated ammonia in a 2 mL microcentrifuge tube.139
Mix on vortex mixer for one minute.140
141
3.2) Prepare 5 mL 16 ng/mL 13C-Aβ1-42 peptide by adding 0.1 mL of 0.8 µg/mL to 4.9 mL142
20% ACN and 4% concentrated ammonia in a 5 mL microcentrifuge tube. Mix on vortex143
mixer for one minute.144
145
4. Preparation of response factor sample146
Note: The response factor (RF) determination is performed to determine the147
concentration of the labeled peptide used for calibration (15N-Aβ1-42). This requires that148
the concentration of the native Aβ1-42 peptide has been determined using amino acid149
analysis (AAA). Thus, the volume and concentration of native Aβ1-42 peptid aliquots need150
to fulfill the requirements of the AAA.151
152
4.1) Prepare 0.5 mL 4 µg/mL native (unlabeled) Aβ1-42 by adding 40 µL of 50 µg/mL153
native Aβ1-42 to 0.46 mL 20% ACN and 4% concentrated ammonia in a 0.5 mL154
microcentrifuge tube. Mix on vortex mixer for one minute.155
156
4.2) Prepare a 2 mL 40 ng/mL mix of native and 15N-Aβ1-42 by adding 20 µL of 4 µg/mL157
native Aβ1-42 and 20 µL of 4µg/mL 15N-Aβ1-42 to 1.96 mL of 20% ACN and 4%158
concentrated ammonia in a 2 mL microcentrifuge tube. Mix on vortex mixer for one159
minute.160
161
4.3) Add 20 µL of the 40 ng/mL mix to 0.38 mL artificial CSF in a 0.5 mL microcentrifuge162
tube. Prepare duplicates and mix on vortex mixer for one minute.163
164
5. Sample preparation165
Note: Thaw samples to be measured at room temperature on a roller.166
167
5.1) Add 0.18 mL of each calibrator, response factor and unknown sample (including168
quality control [QC] samples if used) to a 1 mL protein 96 deep-well plate according to169
Figure 1 (assuming a full plate is used). Make sure to add the samples in, or close to the170
bottom of the wells.171
172
5.2) Add 20 µL of internal standard to each well (i.e., calibrators, response factors, QCs173
and unknowns). It is crucial to release the drop on the side of the well close to the174
surface of the sample without submerging the pipette tip.175
176
5.3) Add 0.2 mL 5 M guanidine-hydrochloride to each well.177
178
5.4) Place the sample plate on a microplate shaker and mix the samples for 45 minutes179
at 1100 rpm. The optimal frequencey might differ depending on instrumentation. Set the180
frequency and amplitude of the mixer so that the solutions are thoroughly mixed and no181
drops of internal standard or CSF are left unmixed on the side of the wells.182
183
5.5) Add 0.2 mL of 4% phosphoric acid to each well. Vortex mix briefly.184
185
6. Solid phase extraction186
Note: In all washing, loading and elution steps, apply lowest possible vacuum after187
adding the solution and gradually increase as needed to load or elute the solution.188
Disable the vacuum between each loading and elution step.189
190
6.1) Put a reservoir tray for waste under a mixed-mode cation exchange 96-well solid191
phase extraction (SPE) plate in the extraction plate manifold chamber.192
193
6.2) Condition the SPE sorbent by adding 0.2 mL methanol to each well.194
195
6.3) Equilibrate the sorbent by adding 0.2 mL 4% phosphoric acid to each well.196
197
6.4) Transfer all samples (about 0.62 mL in each well) from the deep-well plate to the198
SPE plate. It is highly recommended to use an eight channel pipette when transferring199
the samples from the deep well-plate to the SPE-plate. It is not crucial to transfer the200
entire or equal volumes of all samples since the samples contain an internal standard201
which will compensate for variations.202
203
6.5) Wash the sorbent after the samples have passed through by adding 0.2 mL 4%204
phosphoric acid to each well.205
206
6.6) After the washing solvent has eluted from the sorbent, replace the reservoir tray207
with a collection plate or tubes.208
209
6.7) Elute the sample from the sorbent by adding 50 µL 75% ACN/10% concentrated210
ammonia twice. Note that this solution requires very low vacuum to pass through the211
sorbent. Remember to disable the vacuum between each addition.212
213
6.8.1) OPTIONAL. Seal the collection plate or tubes and freeze at -80 °C. Remove the214
seal from the collection plate or tubes before proceeding to 6.8.2.215
216
6.8.2) Dry the eluates by using vacuum centrifugation (without applying heat). This can217
take from one to several hours depending on the vacuum centrifuge.218
219
6.8.3) Seal the containers and freeze at -80 °C.220
221
7. Liquid chromatography222
7.1) Prepare mobile phase A (5% ACN and 0.3% concentrated ammonia in deionized223
water [v/v]), B (4% deionized water and 0.1% concentrated ammonia in ACN [v/v]) and224
needle wash (50% ACN and 4% concentrated ammonia in deionized water [v/v]).225
226
7.1.1) For 500 mL mobile phase A, add 25 mL ACN and 1.5 mL concentrated ammonia227
to deionized water. Adjust the final volume to 500 mL with deionized water.228
229
7.1.2) For 500 mL mobile phase B, add 500 µL concentrated ammonia and 25 mL230
deionized water to ACN. Adjust the final volume to 500 mL with ACN.231
232
7.1.3) Prepare 250 mL needle wash by adding 120 mL ACN and 10 mL to deionized233
water. Adjust the final volume to 250 mL with deionized water.234
235
7.1.4) Put mobile phase A, B and needle wash bottles open in sonication bath for 20236
minutes before use with the LC system237
238
7.2) Dissolve each sample with 25 µL 20% ACN and 4% concentrated ammonia solution239
and place on shaker for 20 minutes. Centrifuge down the sample and place in the240
autosampler (keep at 7 °C).241
242
7.3) Inject 20 µL sample on a 1×250 mm polystyrene-divinylbenzene (reversed-phase)243
monolithic column maintained at 50 °C.244
245
7.4.1) Use the LC gradient shown in the Table 4 with a flow rate of 0.3 mL/min. Divert246
the first two and last five minutes to waste (post column) using a divert valve to reduce247
contamination of the mass spectrometer.248
249
8. Mass spectrometric analysis250
Note: These parameters were used for a quadrupole-orbitrap hybrid mass spectrometer251
equipped with a heated electrospray ionization source.252
253
8.1) Set the parameters for the ion source according to Table 5.254
255
8.2) Set the MS instrument to isolate the 4+ charge states of native Aβ1-42 (1129.48256
mass-to-charge ratio [m/z]), 15N-Aβ1-42 (1143.00 m/z) and 13C-Aβ1-42 (1179.50 m/z) in the257
quadrupole mass analyzer with an isolation width of 2.5 m/z.258
259
8.2) Fragment the isolated peptides in the collision cell with a normalized collision260
energy (NCE) of 17.0. This might need to be tuned for each instrument even of the same261
type (and especially if using other types of instrument, e.g. a triple quadrupole MS).262
263
8.3) Record fragment spectra with a resolution of 17.500 with an automatic gain control264
target of 2×105 charges and a maximum injection time of 250 ms.265
266
9. Data processing267
9.1) Use the sum of the product ions (with a mass tolerance of ±250 milli mass units268
[mmu]) in Table 6 to calculate the chromatographic areas for each peptide. Note that the269
ion types and numbers are only shown for native Aβ1-42 product ions since they are the270
same for both 15N-Aβ1-42 and 13C-Aβ1-42.271
272
9.2) Determine the average response factor of the two response factor samples by273
dividing the area under the curve (chromatographic peak) of 15N-Aβ1-42 with the area274
under the curve of native Aβ1-42.275
276
9.3) Adjust the concentration of the 15N-Aβ1-42 used for calibration by multiplying it with277
the response factor calculated in 9.2.278
279
9.4) Construct a calibration curve by plotting the area ratios of 15N-Aβ1-42 to 13C-Aβ1-42280
from the two sets of calibrators against the concentration.281
282
9.5) Calculate the slope and intercept of the calibration curve suing linear regression.283
284
9.6) Calculate the area ratio of native Aβ1-42 to the internal standard (13C-Aβ1-42) for285
unknown samples.286
287
9.7) Extrapolate the concentration of unknown samples from the calibration curve using288
the slope and intercept obtained in 9.5.289
290
REPRESENTATIVE RESULTS:291
The plate setup in Figure 1 is used for a full plate of samples. If fewer unknown samples292
are to be analyzed, the second calibrator, RF and QC set should be placed after the first293
half of the unknown samples.294
295
As seen in Figure 2, the calibrators are close to the regression line with low standard296
deviations. The method has a lower level of quantification of 150 pg/mL with an upper297
level of quantification of 4000 pg/mL. The residual standard deviation of the calibration298
should of course be as low as possible. If calibration is non-linear the run should be299
discarded (depending on severity) and is most likely due to incorrect pipetting technique300
and/or errors in the dilution of calibrators. The coefficient of variation (CV) of replicates301
should be below 20% but preferably below 10%.302
303
The native, 15N- and 13C-Aβ1-42 elute from the LC column simultaneously (since they only304
differ on the isotopic level) with close to symmetrical peaks without significant tailing305
(Figure 3). At least ten measurements should be performed for each chromatographic306
peak and can be adjusted with the maximum injection time in the instrument method. All307
three peptides can be measured simultaneously for all measurements (calibration, RF308
and unknowns) during the MS analysis. However if the sensitivity of the method is309
suboptimal, only peptides of interest should be measured for each injection, i.e., only310
measure 15N- and 13C-Aβ1-42 for calibrators, native and 15N-Aβ1-42 for RF samples and311
native and 13C-Aβ1-42 for unknown samples.312
313
Figure 1: SPE & deep-well plates layout314
Typical layout of calibrators (A-F), response factor sample (RF), quality control samples315
(QC) and unknowns.316
317
Figure 2: Calibration curve.318
Calibration curve constructed using 15N-Aβ1-42 at 172, 572, 1144, 2287, 3431 and 4574319
pg/mL (adjusted using the response factor) and 13C-Aβ1-42 as internal standard in human320
CSF (n = 2). The area ratio of 15N-Aβ1-42/13C-Aβ1-42 is plotted (Y-axis) against the321
concentration (X-axis).322
323
Figure 3: Chromatogram.324
Chromatogram of 0.500 ng/mL native (endogenous) Aβ1-42 (top panel) and 1.6 ng/mL325
13C-Aβ1-42 (bottom panel) in human CSF.326
327
Figure 4: Quantification of unknown Aβ1-42 in unknown samples328
The peak area ratio is calculated by dividing the native Aβ1-42 chromatographic peak329
area with the internal standard (13C-Aβ1-42) chromatographic peak area. The330
concentration of native Aβ1-42 in the sample is extrapolate from the calibration curve.331
332
Table 1: Safety information333
Safety information for chemicals used for this protocol.334
335
Table 2: Calibrator solutions336
Calibrator solutions prepared in 20% ACN and 4% concentrated ammonia used for337
spiking CSF calibrators.338
339
Table 3: Calibrators340
Calibrators prepared in human CSF.341
342
Table 4: LC gradient343
The LC gradient used with a constant flow-rate of 300 µL/min.344
345
Table 5: Ion source settings.346
Parameters for the ion source to be set in the instrument tune software.347
348
Table 6: Ions used for quantification349
The 4+ charge states of the precursor ions are isolated in the quadrupole mass analyzer350
with an isolation width of 2.5 m/z. The product ions (with a mass tolerance of ±250 mmu)351
are used to calculate the chromatographic areas for each peptide. Ion types and352
numbers are only shown for native Aβ1-42 product ions since they are the same for both353
15N-Aβ1-42 and 13C-Aβ1-42.354
355
DISCUSSION:356
For the described method, instead of using a surrogate matrix we used the surrogate357
analyte approach13-16, which enables calibration in human CSF. The surrogate analyte358
approach involves two different isotopically labeled standards. One (15N-Aβ1-42) is used359
to generate the calibration curve in human CSF while another (13C-Aβ1-42) is used as360
internal standard. Unknown endogenous Aβ1-42 concentrations are then extrapolated361
from the calibration curve constructed using the 15N-Aβ1-42/13C-Aβ1-42 ratio by the362
calculated endogenous Aβ1-42/13C-Aβ1-42 ratio. The surrogate analyte approach was363
used since there is no analyte-free CSF availible, and low Aβ1-42 recovery was observed364
when using native Aβ1-42 in a surrogate matrix during method development.365
366
Since 15N-Aβ1-42 and native Aβ1-42 may give different responses in the MS, the367
concentration of 15N-Aβ1-42 is adjusted by measuring a RF sample – an artificial CSF368
sample containing equal concentrations of 15N-Aβ1-42 and native Aβ1-42 with a known369
concentration determined by AAA. The response factor might differ between different370
mass spectrometers as well as due to possible variations in the isotopic purity of the371
15N-labeled peptide between batches. Thus the response factor should be determined372
for each measurement day.373
374
The most critical steps in this protocol are the preparation of calibrators and RF375
samples. Aβ peptides, and especially the Aβ1-42, are very hydrophobic and easily stick to376
pipette tips and surfaces of tubes8,17,18. To minimize loss of Aβ peptides during pipetting 377
it is extremely important to saturate the pipette tips prior to delivery. Preferably, three378
volumes of peptide solution should be discarded prior to delivery to a new tube379
containing solution. Depending on the volume and concentration of the stock solution380
this is not always possible. The second best approach is of course to pipette the peptide381
solution up and down three times prior to delivery. For the same reason it is important to382
use appropriate sizes for tubes, avoiding large void volumes.383
384
Previously published data for the method shows that recovery was within 100% (15%)15,385
The relative errors for the back-calculated calibrators were below 15% of the whole386
range defined by the calibrator curve19.387
388
One obvious limitation of this technique is its low throughput compared to automated389
immunoassays. However, the purpose of the described method is high accuracy and not390
throughput. This method can also be expanded to include the two shorter Aβ1-38 and391
Aβ1-4019. Another limitation of this method is that the operator will need extensive mass392
spectrometry training before running the analysis on the instrument.393
394
Quantification using immunoassays is dependent on the interaction between the395
antibody and the antigen. This interaction could be affected by the presence of sample396
components that may interfere or compete with the interaction. In addition, the397
interaction may also be affected by the conformation of the antigen. These effects are398
difficult to control and are believed to be the main reason why it has been difficult to399
harmonize results between immunoassay platforms and between laboratories. Because400
quantification with MS is based on directly counting the target molecules relative to a401
stable-isotope labeled standard, quantification is absolute and generally unaffected by402
such matrix effects. In addition, diagnostic protein measurements by immunoassays403
should be supported by an unbroken chain of higher-order of measurement procedures404
and material, from validated LC-MS/MS and stable isotope-labeled internal standards to405
RMPs and a CRM, thus improving results comparability and reliability20,21.406
407
In conclusion, the described RMP for value assignment of Aβ1-42 in CSF is an important408
step in developing a CRM that will help establish general cut-off concentrations for409
Aβ1-42 in CSF. Exact cut-offs are highly important to make an accurate early diagnosis of410
AD, and of utmost importance when the new type of disease-modifying drugs will reach411
the clinic.412
413
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